Last checked at 
LONDON (Alliance News) - Medical imaging software company Feedback PLC on Monday said it has received the results from a large evaluation of TexRAD CT texture analysis as a pre-therapy imaging biomarker in 241 metastatic renal cell cancer patients treated with anti-angiogenic therapy.
The results showed that TexRAD analysis was a "very strong" predictor of overall survival rates at two years and demonstrated itself a strong predictor of overall survival.
"This is a very important study demonstrating the specific application of TexRAD CT texture analysis as a non-invasive imaging biomarker in the management of m-RCC patients treated with AAT," said Balaji Ganeshan, chief scientist and new business officer at the TexRAD Ltd and Cambridge Computed Imaging Ltd subsidiaries of Feedback.
Feedback shares were up 11% to 2.36 pence in early trade, one of the best performers in the AIM All-Share.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
